Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$29.14 +6.7%	$29.14	$23.42 ▼ $62.58	$1.69B	0.77	693,352 shs	476,389 shs
DVAX Dynavax Technologies	$9.85 +4.7%	$12.16	$9.28 ▼ $14.63	$1.18B	1.26	2.22 million shs	4.46 million shs
RCKT Rocket Pharmaceuticals	$7.00 +0.1%	$7.11	$4.55 ▼ $26.98	$746.43M	1.02	1.42 million shs	3.29 million shs
RCUS Arcus Biosciences	$8.82 +6.5%	$8.38	$6.50 ▼ $18.98	$933.38M	0.88	832,638 shs	2.67 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+6.66%	-2.77%	+9.14%	-10.78%	-11.70%
DVAX Dynavax Technologies	+4.68%	-12.52%	-12.44%	-22.44%	-8.20%
RCKT Rocket Pharmaceuticals	+0.43%	-10.83%	+32.83%	-29.15%	-69.19%
RCUS Arcus Biosciences	+6.46%	-1.27%	+9.03%	-26.48%	-47.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3914 of 5 stars	3.3	2.0	4.2	4.1	0.8	1.9
DVAX Dynavax Technologies	4.3254 of 5 stars	3.3	2.0	4.7	2.5	1.7	1.9
RCKT Rocket Pharmaceuticals	4.7933 of 5 stars	4.5	1.0	4.7	3.1	5.0	0.6
RCUS Arcus Biosciences	2.736 of 5 stars	4.5	1.0	0.0	1.1	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.56	Moderate Buy	$56.00	92.18% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	143.65% Upside
RCKT Rocket Pharmaceuticals	2.92	Moderate Buy	$40.82	483.12% Upside
RCUS Arcus Biosciences	2.91	Moderate Buy	$25.67	191.17% Upside

Current Analyst Ratings Breakdown

Latest RCUS, RCKT, AGIO, and DVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $51.00
5/12/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
5/9/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$54.00 ➝ $45.00
5/9/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $44.00
5/9/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
5/2/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$74.00 ➝ $71.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$37.04M	45.57	N/A	N/A	$27.02 per share	1.08
DVAX Dynavax Technologies	$294.62M	4.01	N/A	N/A	$4.81 per share	2.05
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A
RCUS Arcus Biosciences	$141M	6.62	N/A	N/A	$6.17 per share	1.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	2.57	N/A	N/A	1,845.92%	-2.51%	-2.26%	N/A
DVAX Dynavax Technologies	-$6.39M	-$0.52	54.72	20.10	N/A	9.85%	4.22%	2.67%	N/A
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	N/A
RCUS Arcus Biosciences	-$307M	-$4.19	N/A	N/A	N/A	-102.66%	-45.59%	-22.38%	N/A

Latest RCUS, RCKT, AGIO, and DVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A
2/25/2025	Q4 2024	RCUS Arcus Biosciences	-$1.17	-$1.03	+$0.14	-$1.03	$29.38 million	$36.00 million
2/20/2025	Q4 2024	AGIO Agios Pharmaceuticals	-$1.69	-$1.74	-$0.05	-$1.74	$9.35 million	N/A
2/20/2025	Q4 2024	DVAX Dynavax Technologies	$0.05	$0.05	N/A	$0.05	$72.70 million	$72.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	11.90	11.56
DVAX Dynavax Technologies	0.33	13.23	12.34
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05
RCUS Arcus Biosciences	0.08	5.24	5.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
DVAX Dynavax Technologies	96.96%
RCKT Rocket Pharmaceuticals	98.39%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
DVAX Dynavax Technologies	2.98%
RCKT Rocket Pharmaceuticals	28.50%
RCUS Arcus Biosciences	12.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	54.47 million	Optionable
DVAX Dynavax Technologies	350	120.08 million	127.54 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	80.26 million	Optionable

RCUS, RCKT, AGIO, and DVAX Headlines

Recent News About These Companies

Cubist Systematic Strategies LLC Grows Position in Arcus Biosciences, Inc. (NYSE:RCUS)

May 13 at 5:32 AM | marketbeat.com

Q2 EPS Estimates for Arcus Biosciences Cut by HC Wainwright

May 11 at 8:42 AM | marketbeat.com

Q2 Earnings Forecast for Arcus Biosciences Issued By Wedbush

May 11 at 8:42 AM | marketbeat.com

Raymond James Financial Inc. Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS)

May 11 at 3:30 AM | marketbeat.com

FY2025 EPS Forecast for Arcus Biosciences Cut by Analyst

May 11 at 2:39 AM | americanbankingnews.com

HC Wainwright Brokers Decrease Earnings Estimates for RCUS

May 11 at 1:29 AM | americanbankingnews.com

Wedbush Predicts Arcus Biosciences' Q2 Earnings (NYSE:RCUS)

May 11 at 1:29 AM | americanbankingnews.com

Arcus Biosciences, Inc. (NYSE:RCUS) Position Increased by Algert Global LLC

May 10 at 4:56 AM | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Shares Gap Down Following Weak Earnings

May 9, 2025 | marketbeat.com

Wells Fargo & Company Lowers Arcus Biosciences (NYSE:RCUS) Price Target to $26.00

May 9, 2025 | marketbeat.com

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LP

May 9, 2025 | marketbeat.com

Braidwell LP Buys Shares of 802,100 Arcus Biosciences, Inc. (NYSE:RCUS)

May 8, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Sells 538,841 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

May 8, 2025 | marketbeat.com

Renaissance Technologies LLC Lowers Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

May 8, 2025 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Shares Gap Down on Disappointing Earnings

May 8, 2025 | americanbankingnews.com

Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Call Transcript

May 7, 2025 | msn.com

Q1 2025 Arcus Biosciences Inc Earnings Call

May 7, 2025 | finance.yahoo.com

Arcus Biosciences, Inc. (NYSE:RCUS) Receives $28.38 Consensus Price Target from Analysts

May 7, 2025 | americanbankingnews.com

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

May 6, 2025 | seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

May 6, 2025 | zacks.com

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

May 6, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, RCKT, AGIO, and DVAX Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$29.14 +1.82 (+6.66%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$29.14 0.00 (0.00%)

As of 08:00 AM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Dynavax Technologies NASDAQ:DVAX

$9.85 +0.44 (+4.68%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$9.80 -0.05 (-0.56%)

As of 08:01 AM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$7.00 +0.01 (+0.14%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$6.89 -0.11 (-1.57%)

As of 08:05 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Arcus Biosciences NYSE:RCUS

$8.82 +0.54 (+6.46%)

Closing price 05/12/2025 03:59 PM Eastern

Extended Trading

$8.65 -0.17 (-1.88%)

As of 08:02 AM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time